Recent extremely meaningful positive changes in investment behavior have benefitted ImmuCell Corp (NASDAQ: ICCC): the stock rose on very heavy volume, and positive upside/downside volume developed.
Significant positive changes in fundamentals have recently occurred for ImmuCell Corp (NASDAQ: ICCC): significant quarterly earnings acceleration occurred, and significant quarterly sales acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of F. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
ICCC is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
ImmuCell has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. ImmuCell has a poor Appreciation Score of 21 and a poor Power Rating of 20, triggering the Lowest Value Trend Rating.
Recent Price Action
ImmuCell Corp (NASDAQ: ICCC) stock closed at $3.68 on 8/21/24 after a modest gain of 0.5%. Moreover, exceptionally high trading volume at 2098% of normal accompanied the advance. Relative to the market the stock has been weak over the last nine months and has declined -2.1% during the last week.
Be the first to comment